MedTrace Logo

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers

NCT03889366 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-02-25

No results posted yet for this study

Summary

This study will compare the relative bioavailability of both an oral capsule formulation and an oral suspension formulation of NXP001 to Emend® in healthy male volunteers in the fasted state.

Conditions

  • Healthy

Interventions

DRUG

Aprepitant 125 mg

Single dose in the fasted state during treatment period 1,2 or 3

Sponsors & Collaborators

  • Nuformix Technologies Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-20
Primary Completion
2019-04-15
Completion
2019-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03889366 on ClinicalTrials.gov